Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The investigators developed a protocol utilizing once-daily intravenous
busulfan/melphalan/etoposide regimen as a conditioning for high-dose therapy (HDT) in the
patients with high risk or relapsed Non-Hodgkin's Lymphoma (NHL).